文献速递脊柱关节炎

中轴型脊柱关节炎患者减量肿瘤坏死因子抑制剂后复发预测:一项全国性队列研究

Flare prediction after tapering the dose of tumour necrosis factor inhibitors in patients with axial spondyloarthritis: a nationwide cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

基于韩国风湿病学会生物制剂与靶向治疗登记处数据,纳入526例接受标准剂量肿瘤坏死因子抑制剂至少1年并减量的中轴型脊柱关节炎患者,建立减量后1年复发(ASDAS-CRP≥2.1)预测模型,包含8个临床参数,AUC=0.828,低、中、高风险组复发概率分别为4.5%、18.1%和61.8%,并在独立队列中验证性能相当。

要点

  • 最终预测模型包含8个临床参数,区分度AUC=0.828。
  • 低、中、高风险组复发概率分别为4.5%、18.1%和61.8%。
  • 模型在独立验证队列中性能相当。

核心结论

  • 建立的预测模型使用8个简单临床参数可准确预测中轴型脊柱关节炎患者减量肿瘤坏死因子抑制剂后的复发风险。

研究设计与样本

  • 数据来自韩国风湿病学会生物制剂与靶向治疗登记处。
  • 推导队列纳入526例接受标准剂量肿瘤坏死因子抑制剂至少1年并减量的患者。
  • 最终预测模型在独立队列中进行验证。

主要发现

  • 526例患者中127例(24.1%)发生复发。
  • 最终预测模型纳入人类白细胞抗原B27阴性(β=1.088)、炎性背痛(β=1.072)、银屑病(β=1.567)、脊柱关节炎家族史(β=0.623)、糖尿病(β=1.092)、肿瘤坏死因子抑制剂减量≥标准剂量的50%(β=0.435)、减量时ASDAS-CRP(β=1.029)和减量时Bath强直性脊柱炎功能指数评分(β=0.194)作为协变量。
  • 模型区分度AUC=0.828。
  • 低、中、高风险组复发概率分别为4.5%、18.1%和61.8%。

关键数值与推荐

  • 主要结局为肿瘤坏死因子抑制剂减量1年后ASDAS-CRP评分≥2.1定义为复发。

临床怎么用

  • 作者认为该模型有助于在日常临床实践中选择适合减量肿瘤坏死因子抑制剂而不复发的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop a model for predicting flares after tapering the dose of tumour necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). METHODS: Data were obtained from the Korean College of Rheumatology Biologics and Targeted Therapy Registry. In total, 526 patients who received the standard-dose TNFi for at least 1 year and tapered their dose were included in the derivation cohort. The main outcome was a flare occurrence defined as an Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) score of ≥2.1 after 1 year of TNFi tapering. The final prediction model was validated using an independent cohort. RESULTS: Among 526 patients, 127 (24.1%) experienced flares. The final prediction model included negative human leucocyte antigen B27 (β = 1.088), inflammatory back pain (β = 1.072), psoriasis (β = 1.567), family history of SpA (β = 0.623), diabetes mellitus (β = 1.092), TNFi tapering by ≥50% of the standard-dose (β = 0.435), ASDAS-CRP at tapering (β = 1.029), and Bath Ankylosing Spondylitis Functional Index score at tapering (β = 0.194) as covariates. It showed an excellent discrimination performance (AUC = 0.828). According to the predictive risk, patients were classified into three groups (low-, intermediate- and high-risk). The probabilities of flares in these groups were 4.5%, 18.1% and 61.8%, respectively. The performance of the model in the validation cohort was also comparable. CONCLUSION: The established prediction model accurately predicted the risk of flares after TNFi dose tapering in patients with axSpA using eight simple clinical parameters, which could be helpful to select appropriate patients for tapering their TNFi without flare in daily clinical practice.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yeo J, Kim JY, Park JK, et al. Flare prediction after tapering the dose of tumour necrosis factor inhibitors in patients with axial spondyloarthritis: a nationwide cohort study. Rheumatology (Oxford). 2025. PMID: 38479822. doi:10.1093/rheumatology/keae138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。